These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 38824567)

  • 1. A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy.
    Li N; Geng S; Dong ZZ; Jin Y; Ying H; Li HW; Shi L
    Mol Cancer; 2024 Jun; 23(1):117. PubMed ID: 38824567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.
    Sloas C; Gill S; Klichinsky M
    Front Immunol; 2021; 12():783305. PubMed ID: 34899748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR-macrophage versus CAR-T for solid tumors: The race between a rising star and a superstar.
    Chen K; Liu ML; Wang JC; Fang S
    Biomol Biomed; 2024 May; 24(3):465-476. PubMed ID: 37877819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges.
    Kong JC; Sa'ad MA; Vijayan HM; Ravichandran M; Balakrishnan V; Tham SK; Tye GJ
    Front Immunol; 2024; 15():1384039. PubMed ID: 38726000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape.
    Rodriguez-Garcia A; Palazon A; Noguera-Ortega E; Powell DJ; Guedan S
    Front Immunol; 2020; 11():1109. PubMed ID: 32625204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges and strategies in relation to effective CAR-T cell immunotherapy for solid tumors.
    Yuan G; Ye M; Zhang Y; Zeng X
    Med Oncol; 2024 Apr; 41(5):126. PubMed ID: 38652178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineered CD147-CAR macrophages for enhanced phagocytosis of cancers.
    Chupradit K; Muneekaew S; Wattanapanitch M
    Cancer Immunol Immunother; 2024 Jul; 73(9):170. PubMed ID: 38954079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric antigen receptor-immune cells against solid tumors: Structures, mechanisms, recent advances, and future developments.
    Li X; Li W; Xu L; Song Y
    Chin Med J (Engl); 2024 Jun; 137(11):1285-1302. PubMed ID: 37640679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAR-NK Cells: From Natural Basis to Design for Kill.
    Khawar MB; Sun H
    Front Immunol; 2021; 12():707542. PubMed ID: 34970253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions.
    Bagley SJ; O'Rourke DM
    Pharmacol Ther; 2020 Jan; 205():107419. PubMed ID: 31629009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Solid Tumors Challenges and New Insights of CAR T Cell Engineering.
    Tahmasebi S; Elahi R; Esmaeilzadeh A
    Stem Cell Rev Rep; 2019 Oct; 15(5):619-636. PubMed ID: 31161552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Car T Cells in Solid Tumors: Overcoming Obstacles.
    Rojas-Quintero J; Díaz MP; Palmar J; Galan-Freyle NJ; Morillo V; Escalona D; González-Torres HJ; Torres W; Navarro-Quiroz E; Rivera-Porras D; Bermúdez V
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review.
    Satapathy BP; Sheoran P; Yadav R; Chettri D; Sonowal D; Dash CP; Dhaka P; Uttam V; Yadav R; Jain M; Jain A
    Front Immunol; 2024; 15():1389971. PubMed ID: 38799440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
    Hong M; Clubb JD; Chen YY
    Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies.
    Niu Z; Wu J; Zhao Q; Zhang J; Zhang P; Yang Y
    Front Immunol; 2024; 15():1385571. PubMed ID: 38680498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surmounting the obstacles that impede effective CAR T cell trafficking to solid tumors.
    Donnadieu E; Dupré L; Pinho LG; Cotta-de-Almeida V
    J Leukoc Biol; 2020 Oct; 108(4):1067-1079. PubMed ID: 32620049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deciphering the tumor immune microenvironment from a multidimensional omics perspective: insight into next-generation CAR-T cell immunotherapy and beyond.
    Zhou Z; Wang J; Wang J; Yang S; Wang R; Zhang G; Li Z; Shi R; Wang Z; Lu Q
    Mol Cancer; 2024 Jun; 23(1):131. PubMed ID: 38918817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent Advances in CAR-Based Solid Tumor Immunotherapy.
    Shin MH; Oh E; Kim Y; Nam DH; Jeon SY; Yu JH; Minn D
    Cells; 2023 Jun; 12(12):. PubMed ID: 37371075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.